Numerous neurodegenerative diseases, infections, metabolic anomalies, and toxins can result in progressive dementia.^[@R1]^ Many cases are reversible if treated in the early stages; thus, timely diagnosis by the identification of the causative agent based on extensive examination is required. Infectious encephalitis or encephalomyelitis is an important cause of treatable dementia and comprises a variety of diseases, including herpes simplex virus 1 and 2 infection, cytomegalovirus infection, Epstein-Barr viral infection, HIV infection, neurosyphilis, mycobacterial infection, Whipple disease, neuroborreliosis, *Bartonella henselae* infection, cryptococcal meningitis, malaria, and trypanosomiasis.^[@R2]^ These diseases and infections are usually accompanied by other hallmarks of infection. Furthermore, geographical clustering of patients is a strongly suggestive factor for infectious diseases.

In 2005, we encountered a patient with severe early-onset dementia. Histopathology of biopsied brain tissue revealed encephalitis. The putative pathogen was cell wall deficient and exhibited several unreported features. In the following 7 years, we treated 3 additional patients presenting with similar clinical symptoms and pathologic findings. All patients inhabited towns located on a peninsula of Kyushu Island, Japan. Here we describe the clinical, pathologic, and radiologic findings of this disease and report results of genomic screening for preliminary identification of the causative pathogen.

METHODS {#s1}
=======

Patient 1. {#s1-1}
----------

The first patient presenting with this unique form of encephalomyelitis was a 47-year-old man from a fishing town on Kyushu Island. Three months before admission, he started eating excessively. His speech and daily activities decreased for a few weeks, accompanied by memory disturbance and disorientation. Two physicians made an initial diagnosis of Alzheimer disease. No abnormalities were observed on blood analyses or MRI during the first 3 months after onset; however, from the fourth month, elevated CSF cell count was observed and fluid-attenuated inversion recovery (FLAIR) MRI revealed high signal intensity regions in the dorsal pons, bilateral insular cortex, and subcortical temporal region ([figure 1, A--C](#F1){ref-type="fig"}). Neurologic examination revealed severe disorientation, loss of calculation, and memory disturbance. Dystonic tongue movements and intermittent myoclonic movements of the limbs were also observed; however, ambulation was normal. Physical examination revealed hyperreflexia in extremities, a positive sucking reflex, and positive Babinski and Chaddock signs.

![Initial brain imaging\
(A--C) patient 1; (D--F) patient 2; (G--I) patient 3; (J--L) patient 4; and (M) patient 2. Brain fluid-attenuated inversion recovery (FLAIR) MRI performed on admission (A--C) revealed abnormally high intensity at the dorsal pons, bilateral insular cortex, and subcortical region in patient 1. According to FLAIR MRI, patient 2 and patient 4 had similar brain lesions, including abnormalities around the inferior horn of the lateral ventricle (D, J) and diffuse high intensity in the deep white matter of the frontotemporoparietal regions (E, K). These lesions are mainly confined to the white matter, as revealed by the relative sparing of the cortex, and are enhanced by gadolinium administration in T1-weighted MRI (F, L). In contrast, FLAIR MRI of patient 3 revealed patchy lesions in the subcortical area of the left temporal lobe (G) and in the basal ganglion (H). Contrast-enhanced FLAIR MRI revealed hyperintense lesions along the left central sulcus (I). Sagittal T2-weighted images depict an inhomogeneously hyperintense spinal cord, stretching from the cervico-occipital junction to the thoracic cord region (M).](NEURIMMINFL2014003863FF1){#F1}

Hematologic data were normal, whereas white blood cell (WBC) count (27 cells/μL) and protein level (78 mg/dL) were elevated in CSF, strongly suggesting an infection or autoimmune disease; however, tests for serum autoantibodies and known infectious agents associated with encephalomyelitis were all negative (table e-1 at [Neurology.org/nn](10.1212/NXI.0000000000000143)).

The patient was initially administered ceftriaxone, streptomycin, methylprednisolone, and IV immunoglobulin for infectious or autoimmune encephalitis, which slightly improved his symptoms during the first 2 weeks of treatment; however, the recovery ceased thereafter, and brain MRI indicated enlargement of the lesions, particularly in the lower temporal lobes (figure e-1A). Whipple disease was considered as a potential diagnosis, although only a few patients with this disease had been reported in Japan.^[@R3][@R4][@R5]^ However, the absence of periodic acid-Schiff (PAS)--positive macrophages in duodenal biopsy argued against *Tropheryma whipplei* infection. Subsequently brain biopsy was performed and the potential infectious organism was ultrastructurally and genetically characterized.

Electron microscopic analysis of brain biopsy tissue revealed a round- to oval-shaped pathogen. Treatment with high-dose trimethoprim/sulfamethoxazole (TMP-SMX) (1 g of TMP-SMX contained 400 mg sulfamethoxazole and 80 mg trimethoprim, administered at a maximum dose of 12 g/day) plus prednisolone was started. The patient\'s symptoms improved daily after treatment initiation. After 3 months the patient\'s orientation, writing ability, memory, motivation, and calculation ability recovered. In 5 months he was capable of handling most daily activities, and 2 months later he could use the Internet and commence work. Seven years after onset, memory disturbance and disorientation recurred following withdrawal of medication; thus, treatment with TMP-SMX was reinitiated (8 g/day) and the patient gradually recovered (figure e-1C). Figure e-2 summarizes the clinical course of this first patient.

Detailed clinical data on patients 2--4 are described in appendix e-1.

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

All 4 patients with progressive dementia (referred by neurologists) were examined and treated at Kagoshima University Hospital. Relatives of the patients provided written informed consent for study participation. The Institutional Review Board of Kagoshima University approved the study.

Histopathology. {#s1-3}
---------------

Brain biopsies were performed in all 4 patients. Tissue blocks were fixed in 4% paraformaldehyde in 0.1 M phosphoric acid buffer and embedded in paraffin. Paraffin sections were subsequently stained with hematoxylin and eosin (H&E), Gram stain, Grocott stain, and PAS. Serial tissue sections were stained with anti-CD4 (Nichirei Corp., Tokyo, Japan), anti-CD8, and anti-CD68 (Dako, Glostrup, Denmark). Smaller specimens were fixed in 3% glutaraldehyde in 0.1 M phosphoric acid buffer and embedded in Epon 812.

Amplification of 16S/18S ribosomal RNA. {#s1-4}
---------------------------------------

DNA samples were isolated from the CSF of all patients and from the biopsied brain samples of patients 3 and 4. Universal primer sets were designed on the basis of previous reports targeting 16S/18S ribosomal RNA (rRNA) from bacteria, fungi, and archaea (table e-2). PCR was performed following standard protocols using KOD-Plus-Neo (Toyobo, Osaka, Japan).

Unbiased high-throughput sequencing. {#s1-4-1}
------------------------------------

The pathogens found in brain tissue sections of patients 3 and 4 by PAS staining were isolated using a laser microdissection (LMD) system (Leica Microsystems, Wetzlar, Germany). Brain tissues obtained from patients 1 and 2 were excluded from this genetic analysis because in these initial cases no special measures were taken to avoid microbial contamination during specimen handling. In addition, 3 biopsied brain samples, 1 each of papillary meningioma, intravascular lymphomatosis, and glioblastoma, were used as controls. Genomic DNA was extracted from the CSF and LMD samples using a DNA blood and tissue extraction kit (QIAGEN, Tokyo, Japan). Unbiased high-throughput genomic sequencing was performed using a next-generation sequencing system (MiSeq, NextraXT prep kit, Illumina, San Diego, CA) and a paired-end sequencing approach starting with 1 ng genomic DNA. A higher-quality read was obtained by trimming the 3′ end when the average quality value was lower than 20. For identification of nonhuman DNA, the CLC Genomics Workbench (CLC bio, Aarhus, Denmark) was used to search a human genome database (UCSC: hg19) and a human messenger RNA database (RefSeq release 54) and eliminate most human sequences. The remaining unmapped reads were subsequently analyzed by Nucleotide BLAST against the database (GenBank Release 191) from the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/genbank/>), with a cutoff E-value of \<1e^∼20^ and hit length of \>80 bases.

Pathogen-specific primer design and nested PCR. {#s1-5}
-----------------------------------------------

To validate the existence of pathogen DNA detected by unbiased high-throughput sequencing, oligonucleotide primers were designed targeting the sequenced fragments, and nested PCR was conducted using DNA obtained by LMD from patient 3.

RESULTS {#s2}
=======

Patient characteristics. {#s2-1}
------------------------

The onset age of the 4 patients ranged from 47 to 70 years. At onset, the disease was characterized by dementia and involuntary tongue movement. Slowly progressive dementia with motor disturbances emerged within 1 year of onset. Patients exhibited varied clinical phenotypes, including pyramidal signs, parkinsonism, and cerebellar ataxia. On presentation at our institution, all patients exhibited moderate to severe dementia according to the revised Hasegawa Dementia Scale and the Mini-Mental State Examination.^[@R6]^ In addition, all patients exhibited pleocytosis (7--64 cells/μL, predominantly mononuclear cells) and elevated protein in the CSF. The CSF levels of C-X-C motif chemokine 13 (CXCL13) were \>500 pg/mL (normal: undetectable) in all patients prior to TMP-SMX administration according to ELISA (R&D Systems, Abingdon, UK). After administration of TMP-SMX and corticosteroid combination therapy, CSF CXCL13 decreased to 466 pg/mL in patient 1, 211 pg/mL in patient 2, 30.7 pg/mL in patient 3, and 22.2 pg/mL in patient 4. Clinical histories, physical examination results, and laboratory test results for all 4 patients are summarized in [table 1](#T1){ref-type="table"}.

###### 

Initial evaluation of 4 patients with progressive dementia

![](NEURIMMINFL2014003863TT1)

All patients exhibited hypointensities on FLAIR images, and the lesions were slightly enhanced by gadolinium. These lesions were spread throughout the brain but were particularly noticeable in the subcortical white matter of the temporal lobe. The cortex, basal ganglia, brainstem, and spinal cord could be involved at more advanced stages ([figure 1](#F1){ref-type="fig"}). These abnormalities also improved with TMP-SMX and prednisolone combination therapy (figure e-1).

Histopathology. {#s2-2}
---------------

Brain tissue samples from the 4 patients showed comparable histopathologic changes consisting of perivascular spongiosis and infiltration of mononuclear cells ([figure 2, E and F](#F2){ref-type="fig"}). Subcortical changes were more prominent than cortical changes, and there was slight white matter gliosis. No aggregates of foamy macrophages were seen, but microabscess formation was observed in patient 3. Moreover, infiltration of inflammatory cells was observed in the subarachnoid space. No significant necrosis, hemorrhage, neuronophagia, or demyelination was found.

![Histochemical and immunohistochemical staining and electron microscopic examination of structures in the brain biopsy\
Hematoxylin & eosin staining (A), periodic acid-Schiff (PAS) staining (B), and Grocott staining (C) of brain biopsy samples show the presence of round pathogens, similar to Michaelis-Gutmann bodies, located mainly around the blood vessels. Some CD4-positive T lymphocytes are also located around the vessels (D). CD8-positive T lymphocytes appear to be the main invasive cells (E), whereas CD68-positive macrophages are only present in patches (F). Toluidine blue and Safranin O stain of Epon-embedded semithin sections show some pathogens without nuclei around vessels (G). Electron microscopy (H--J) shows an irregular shape of pathogens (diameter 2--7 μm) without cell walls and nuclei (arrows) but with some membranous structures in the cytoplasm (triangles). Scale bar = 5 μm. Brain biopsies from patients 2 (K), 3 (L), and 4 (M) demonstrate a similar histopathology to that of patient 1, with 2--7 μm round PAS-positive pathogens located mainly around the vessels. The agents showed an irregular shape with no detectable cell wall or nucleus under an electron microscope (arrows). Scale bar = 5 μm.](NEURIMMINFL2014003863FF2){#F2}

No pathogen was identified in H&E-stained sections, but PAS staining revealed round- to oval-shaped bodies (2--7 μm in diameter) in the extracellular area and cytoplasm of macrophages infiltrating the perivascular region ([figure 2, B, K--M](#F2){ref-type="fig"}). Part of these structures morphologically resembled Michaelis-Gutmann bodies. These bodies were positive for Grocott stain ([figure 2C](#F2){ref-type="fig"}) but negative for Gram stain and immunostaining against toxoplasma antigen. Electron microscopy revealed that these bodies were anuclear cells of irregular shape and varying size. They lacked a nuclear membrane and cell wall but showed occasional cytoplasmic structures ([figure 2, H--J](#F2){ref-type="fig"}).

Genomic analysis and gene sequence--based analysis using 16S/18S rRNA. {#s2-3}
----------------------------------------------------------------------

No amplicon products of bacterial, fungal, protozoal, or archaeal origin were obtained from CSF or brain tissue DNA using previously described universal primer pairs targeting 16S/18S rRNA.

Pathogen detection by unbiased next-generation sequencing and nested PCR. {#s2-4}
-------------------------------------------------------------------------

Among 7,292,715 DNA fragments obtained from patient 3, 130 reads showed a striking homology to Halobacteriaceae (domain Archaea) under conditions E-value \<1e^−20^, hit length \>80, and identity \>70% ([figure 3](#F3){ref-type="fig"}, table e-3). These sequences were not substantially homologous to known bacteria or eukarya sequences (E-value \> 1e^3^). Moreover, of 303,698 DNA fragments isolated from patient 4, 126 reads also showed a high degree of homology with Halobacteria, particularly *Halorubrum lacusprofundi* and *Halophilic archaeon* ([figure 3](#F3){ref-type="fig"}, table e-3). In contrast, genomic DNA extracted from brain tissues of patients with papillary meningioma (4,760,858 reads), intravascular lymphomatosis (5,259,934 reads), or glioblastoma (5,027,830 reads) showed no significant homology to known archaeal genomic or mRNA sequences (data not shown).

![Stepwise strategy of bioinformatic analysis of sequencing results\
We obtained 7,292,715 and 303,698 DNA sequence reads from the affected brain tissues of patients 3 and 4, respectively. After trimming off low-quality sequence regions, we mapped them to the human genome and messenger RNA (mRNA) reference sequences using CLC Genomics Workbench. The 272,518 reads from patient 3 (3.7% of the total reads) and the 56,534 reads from patient 4 (18.6% of the total reads) that aligned with neither the human genome nor the mRNA reference sequences were further analyzed using BLASTN against the nucleotide database with a cutoff E-value of \<1e^∼20^. LMD = laser microdissection; NCBI = National Center for Biotechnology Information; PAS = periodic acid-Schiff.](NEURIMMINFL2014003863FF3){#F3}

No amplification of target sequences was obtained from CSF- or LMD-derived DNA of patient 3 and 4 using primers targeting the fragments homologous to *Halobacterium* (data not shown).

DISCUSSION {#s3}
==========

We report a new type of encephalomyelitis in 4 unrelated Japanese patients. All patients exhibited comparable clinical, radiologic, and histopathologic features, suggesting a shared pathogen. All inhabited a small Japanese island, but no direct person-to-person contact or other mode of transmission was identified; thus, we assumed that other people in this region may be exposed to the causative pathogen, but few are infected.

Progressive disease course, abnormal cytologic results, elevated CXCL13, and radiologic diversity suggested an infectious entity; however, common clinical features of infectious encephalitis, such as fever, increased number of WBCs in peripheral blood count, or elevation of C-reactive protein, were absent. Rather, slow progression and mild pathologic changes in the brain indicated a relatively moderate host immune response, indicative of the weak toxicity or virulence of the pathogen. In addition, CSF samples did not show any oligoclonal IgG bands (OCBs) in the patients. The OCB-negative data do not rule out infectious encephalitis because OCBs are detected more frequently in the CSF of patients with herpes simplex encephalitis; however, they are less frequently detected in the CSF of patients with other CNS infections.^[@R7]^ The aggregation of inflammatory changes around blood vessels in brain tissue indicated that the pathogen probably invades the CNS through the vasculature.

The common clinical characteristics of these patients (progressive dementia, involuntary tongue movements, CSF abnormalities, and responsiveness to TMP-SMX therapy) are also shared by patients with Whipple disease, a rare systemic infectious disease caused by the bacterium *T whipplei*.^[@R8],[@R9]^ However, facial myorhythmia, a central feature of Whipple disease, was not observed in our patients, and PAS-positive macrophages in the duodenum, another defining feature of Whipple disease, were absent. In addition, the ultrastructural features of the putative infectious agent observed in the perivascular spaces and within infiltrating macrophages differed substantially from those of *T whipplei* ([figure 4](#F4){ref-type="fig"}), and no *T whipplei*--specific nucleotide sequences were revealed by genomic sequencing.

![Diagram of various known microbes and the present pathogen\
On the basis of morphologic features, the microbes could be categorized into 5 groups: virus, bacteria, fungi, protozoa, and archaea. The present pathogen is characterized by irregular shape, varying size (2--7 μm), a membrane structure, and absence of both cell wall and nucleus. These morphologic features are distinguishable from those of viruses (diameter 0.02--0.3 μm), known pathogenic bacteria (with a cell wall or differences in size), fungi (with a cell wall and nucleus), or protozoa (with a nucleus) but analogous to 2 types of archaea, *Thermoplasma* and *Ignicoccus*.](NEURIMMINFL2014003863FF4){#F4}

Brain MRI revealed widely distributed lesions, particularly in the subcortical white matter of the temporal lobes. Lesions in temporal lobe structures or associated efferent and afferent pathways can result in dementia manifesting as memory disturbances and disorientation. Additional spinal cord involvement was observed in patient 2. All these lesions reduced markedly in size or disappeared after TMP-SMX therapy. The responsiveness of these MRI lesions to combination antibiotic--steroid therapy is further evidence of infectious encephalomyelitis. Histologic changes included perivascular spongiosis, cuffing of mononuclear cells in gray and white matter, and subarachnoid infiltration without neuronal degeneration. Perivascular changes were predominant in the white matter, consistent with the MRI findings.

The pathogen was not visible using routine H&E staining. Using PAS staining, however, we observed round to oval bodies in spongiotic perivascular regions of the affected brain tissue. These bodies were also Grocott-positive. No nuclei or cell walls were recognized by histologic and ultrastructural analyses. These bodies ranged in size from 2 to 7 μm, larger than any known pathogenic bacterium. Some prokaryotes do not have a cell wall, including *Mycoplasma* among bacteria and *Thermoplasma* and *Ignicoccus* among archaea ([figure 4](#F4){ref-type="fig"}).^[@R10]^ *Thermoplasma* tend to fuse and are therefore highly irregular in shape, similar to the pathogen observed in this study (figure e-3, amended with permission from American Society for Microbiology © 1995, Yasuda et al^[@R10]^). Moreover, inhibition of cell wall synthesis by ceftriaxone induces morphologic alterations in common bacteria^[@R11]^; however, patients 3 and 4 were not treated with antibiotics before brain biopsy.

Unbiased high-throughput sequencing has proven effective for the identification of infectious pathogens.^[@R12][@R13][@R14]^ Using this method, we successfully identified more than 100 sequences closely homologous to the genome of Halobacterial species from the DNA samples of 2 patients (table e-3). Therefore, we propose that this unknown pathogen genetically resembles *Halobacterium*, a genus of the domain Archaea. Based on unique ultrastructural features and sequence homology, we suggest that the causative pathogen is a *Halobacterium*. Unfortunately, no amplicon products were obtained from brain tissue or CSF of patients 3 and 4 using multiple archaeal universal primers or fragment-specific primers. This may be attributed to the low amount of target pathogen DNA obtained, the high mutation rate of the archaeal genome, or the lower sensitivity of nested PCR, which can lead to false-negative results.^[@R15]^

No evidence of CNS disorders due to archaeal infection has been reported. The domain Archaea, one of the 3 domains of living organisms together with eukarya and bacteria,^[@R16]^ is a highly diverse and abundant group of prokaryotes usually inhabiting extreme environments such as salt lakes, deep seas, and hot springs.^[@R14]^ They have also been detected in the human vagina, colon, and oral cavity.^[@R17],[@R18]^ In 2003, the pathogenicity and disease association of archaea were precisely forecasted*.*^[@R19]^ Although the virulence of these organisms has not been confirmed, the relationship between the severity of periodontal disease and the abundance of archaeal rRNA in the subgingival crevice has been reported.^[@R17]^

Given the abundant evidence of an infectious entity, various antibiotics, including ampicillin, ceftriaxone, streptomycin, and minocycline, were administered, none of which proved effective. In contrast, TMP-SMX plus corticosteroids had a rapid curative effect in all 4 patients. TMP-SMX monotherapy did not produce a complete therapeutic effect, suggesting that an anti-inflammatory is also required.^[@R9]^ We recommend a high dose of TMP-SMX (6--12 g/day) plus steroids as first-line treatment, as this regimen dramatically reversed symptoms in patients 1 and 3 without severe adverse events. However, patients 2 and 4 developed acute liver failure as a side effect of high-dose TMP-SMX, and neurologic symptoms gradually deteriorated upon TMP-SMX withdrawal. Patient 2 was then treated with lower-dose TMP-SMX intermittently for 5 years with substantial symptom improvement, whereas patient 4 deteriorated to a vegetative state and died despite reexposure to low-dose TMP-SMX (2 g/day) in combination with corticosteroids.

We attempted to cultivate the pathogen from the biopsied brain sample of patient 3 using a medium containing 15% or 20% NaCl under aerobic conditions. However, the cultivation was unsuccessful, possibly because our tissue preservation protocol may not be appropriate for organisms without cell walls, such as *Mycoplasma*, which are sensitive to mechanical stress.^[@R20]^ In this study, the target pathogen could have been destroyed by mechanical stressors such as ice crystals because all biopsied brain samples were preserved without cryoprotectants.

We propose a new disease entity for infectious encephalomyelitis identified in 4 Japanese patients on the basis of the following criteria: (1) geographical clustering; (2) comparable clinical features, including progressive dementia with involuntary tongue movements; serum and CSF cytologic examination; similar lesion patterns on MRI; and sensitivity to TMP-SMX; and (3) unique ultrastructural characteristics of the undescribed pathogen. Using unbiased high-throughput sequencing, the potential pathogen was tentatively identified as a species of archaea, despite the subsequent unsuccessful genetic or cellular studies. As the next step, we need to clarify the pathogenicity of the PAS-positive agent by immunohistochemical studies using patient serum. Further experiments are required to validate archaea as the causative agent and to identify the specific species, natural host, route of transmission, pathogenic mechanism, and epidemiology. We recommend the application of high-dose TMP-SMX therapy to this encephalomyelitis. Our work will shed light on an undiagnosed encephalomyelitis.
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